Sonic Incytes Medical Corp. news
Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M Series A with backing from Nimbus Synergies as the lead investor, and support from Nicola Wealth, Mint Venture Partners, Consortium Medteq, Wavemaker Three-Sixty Health, Gaingels and INP Capital, as well as notable angel investors.
The strategic equity round, which was oversubscribed by 150%, comes after the launch of Velacur
Greater measurement depth of novel imaging test for liver disease highlighted in presentation
Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of VelacurTM – the first handheld 3D liver health assessment solution – will be presented during the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, hosted virtually November 12-15, 2021.
When measuring fatty liver di
Breakthrough imaging solution for liver health offers physicians an accurate, accessible and affordable way to manage emerging health crisis
In recognition of Liver Awareness Month this October, Sonic Incytes Medical Corp. is pleased to showcase VelacurTM, the first handheld 3D liver health assessment solution, at the American College of Gastroenterology (ACG) Annual Scientific Meeting, Oct 22-27. Attending physicians are invited to visit the VelacurTM booth,
MedTech Innovator, the largest accelerator of medical device companies in the world, in partnership with
If you’re ready to transform your liver practice, we’re ready to show you how.
Discover how fast, accurate and easy VelacurTM is to assess liver health at the inaugural Liver Connect conference, April 16-17, 2021, hosted by the Chronic Liver Disease Foundation. Visit our in-person booth for live demos of Velacur, the first handheld 3D liver health assessment solution.
Developed by Sonic Incytes Medical Corp., VelacurTM is a break